GLP-1 Receptor Agonists for Cardiovascular and Kidney Health in Type 2 Diabetes

GLP-1 receptor agonists have strong evidence from cardiovascular outcome studies, showing significant reductions in major adverse cardiovascular events (MACE) and a slower progression of diabetic kidney disease in individuals with type 2 diabetes mellitus (T2DM).

Semaglutide, a specific GLP-1 receptor agonist, has demonstrated superior reductions in hemoglobin A1C and body weight compared to other available treatments.

The American Diabetes Association (ADA) and Kidney Disease: Improving Global Outcomes (KDIGO) guidelines recommend GLP-1 receptor agonists for patients who have atherosclerotic cardiovascular disease, are at high cardiovascular risk, or have chronic kidney disease (CKD), especially when they require improved glycemic control or weight loss. These agents are also preferred for T2D patients with CKD when other medications are not sufficient to achieve glycemic targets.